Joie Armstrong asked her doctor about taking a GLP-1 medication to help her lose weight six times before she got a prescription, and then was denied coverage by her insurance company. Adrian, a ...

Previous studies have related tirzepatide use with improved eGFR and urine albumin-creatinine ratio (UACR) among patients with type 2 diabetes (T2D) and overweight or obesity. It remains unclear ...

Last year she bought a compounding pharmacy's version of tirzepatide, paying about $470 monthly, and had lost more than 20 pounds when the FDA announced the ban on compounded weight-loss drugs.

Lilly said it had taken many steps to address patient safety risks posed by the proliferation of unsafe or untested tirzepatide. The company said it is filing lawsuits, educating consumers and working ...

Study Overview: Eli Lilly and Company is conducting a clinical study titled ‘Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...

People with obesity and prediabetes assigned tirzepatide were more likely to have sustained weight loss than those assigned placebo. Most people on tirzepatide sustained weight loss through 176 weeks.

In SAT, 0602K and tirzepatide each produced marked decreases in adipocyte (fat cell) size, with the combination decreasing adipocyte size dramatically more than either alone.